Brofaromine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Brofaromine
Brofaromine.svg
Systematic (IUPAC) name
4-(7-bromo-5-methoxybenzofuran-2-yl)piperidine
Clinical data
  • (Prescription only)
Oral
Pharmacokinetic data
Protein binding 98%
Half-life 9-14 hours
Identifiers
63638-91-5 YesY
None
PubChem CID 44571
ChemSpider 40549 YesY
UNII 6WV4B8Q07H YesY
KEGG D02560 YesY
ChEMBL CHEMBL160347 YesY
Chemical data
Formula C14H16BrNO2
310.186 g/mol
 YesY (what is this?)  (verify)

Brofaromine (Consonar) is a reversible inhibitor of monoamine oxidase A discovered by Ciba-Geigy.[1] The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.[2]

Brofaromine also has serotonin reuptake inhibitory properties and its dual pharmacologic effects offer promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with standard drugs.

Pharmacology[edit]

Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.

References[edit]

  1. ^ US Patent 4210655
  2. ^ Lotufo-Neto F, Trivedi M, Thase ME (1999). "Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression". Neuropsychopharmacology 20 (3): 226–47. doi:10.1016/S0893-133X(98)00075-X. PMID 10063483.  Free full text